Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$147.00K$147.00Kderived−46.5% vs Q4 2016 Net Income-$4.33M-$4.33MderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,859,000N/M Operating Cash Flowderived-$3,765,000N/M Free Cash Flowderived-$4,279,000N/M Margins · derivedOperating margin-2625.2%−1623.7 pt vs Q4 2016
Net margin-2944.9%−1971.4 pt vs Q4 2016
ended Jun 30, 2017 · filed Sep 15, 2017 · 77 d after period end